Identifying Who Should Not Get Dental Implants Before Starting the Journey

The determination of implant candidacy has evolved from empirical opinion to data-driven guidelines. To accurately define who should not get dental implants, one must synthesize findings from longitudinal cohort studies, systematic reviews, and meta-analyses. The academic literature delineates clear risk factors that statistically increase the Odds Ratio (OR) of implant failure.  This article by Luxe Smile Studio aggregates current peer-reviewed evidence to provide a consensus on absolute and relative contraindications.

Metabolic Syndromes and Failure Rates

The literature extensively covers the impact of glycemic control.

The HbA1c Threshold

A systematic review published in the International Journal of Oral & Maxillofacial Implants correlates HbA1c levels with implant survival. The consensus indicates that while well-controlled diabetes yields survival rates comparable to healthy patients, poorly controlled diabetes (HbA1c > 8.0%) shows a statistically significant increase in peri-implantitis and early failure. The mechanism cited is the formation of Advanced Glycation End-products (AGEs) which impair collagen homeostasis. Evidence-based guidelines suggest that patients exceeding this glycemic threshold fall into the category of who is not suitable to get dental implants until metabolic stabilization is achieved.

The Bisphosphonate Controversy

Pharmacological contraindications remain a subject of intense research.

IV vs. Oral Administration

The risk of Medication-Related Osteonecrosis of the Jaw (MRONJ) is the primary concern. Literature differentiates sharply between oral and intravenous administration.

• Oral Bisphosphonates: Studies indicate a very low incidence of MRONJ (< 0.1%), suggesting oral use is not an absolute contraindication.
• IV Bisphosphonates: The risk escalates significantly (1-10%) in cancer patients receiving high-dose IV therapy. Current position papers from the American Association of Oral and Maxillofacial Surgeons (AAOMS) classify patients on active IV antiresorptive therapy as high-risk candidates. Consequently, the academic consensus identifies this group as who should not get dental implants due to the severity of potential sequelae.

Age-Related Findings: Skeletal Maturation

When is a patient biologically ready?

Facial Growth Analysis

Longitudinal cephalometric studies confirm that vertical facial growth continues well into the second decade of life. A study in the Journal of Clinical Periodontology highlighted that implants placed in adolescents behaved like ankylosed teeth, resulting in infra-occlusion (submergence) as the adjacent dentition continued to erupt. The literature establishes a firm exclusion criterion: who should not get dental implants includes any patient without confirmed cessation of skeletal growth, verified via serial cephalometric radiographs or hand-wrist films.

Summary of Consensus

Research supports a hierarchy of contraindications.

1. Absolute: Recent MI (heart attack), valvular prosthesis surgery, immunosuppression, IV bisphosphonates, active malignancy.
2. Relative: Smoking (OR 2.0 for failure), Bruxism, Diabetes (controlled). The data emphasizes that "relative" risks are cumulative. A patient who smokes and has diabetes presents a synergistic failure risk that often shifts them into the absolute exclusion category.

The synthesis of current dental literature provides a robust framework for patient selection. Evidence supports the exclusion of metabolically unstable, skeletally immature, and pharmacologically compromised patients. By adhering to these evidence-based exclusion criteria regarding who should not get dental implants, clinicians align their practice with the highest probability of statistical success.